2. Immunology/Inflammation
  3. MyD88
  4. ST 2825

ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity.

For research use only. We do not sell to patients.

ST 2825 Chemical Structure

ST 2825 Chemical Structure

CAS No. : 894787-30-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 1905 In-stock
Solution
10 mM * 1 mL in DMSO USD 1905 In-stock
Solid
1 mg USD 426 In-stock
5 mg USD 1464 In-stock
10 mg USD 2227 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 77 publication(s) in Google Scholar

ST 2825 Related Antibodies

Top Publications Citing Use of Products

67 Publications Citing Use of MCE ST 2825

WB

    ST 2825 purchased from MedChemExpress. Usage Cited in: J Cell Physiol. 2019 May;234(5):7645-7658.  [Abstract]

    Western blot analysis shows the level of NFATc1 in cells stimulated with RANKL in the presence or absence of ST 2825.

    ST 2825 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2018 Aug 22;64:33-41.  [Abstract]

    Western blot analysis of the protein levels of the phosphorylated NF-κB P65 levels, and the phosphorylated ERK levels in U251 cells, pre-treated with the indicated concentrations of ST2825 (ST) for 24 h, and re-treated with 1 μg/mL LPS for 1 h.

    ST 2825 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Oct;16(4):4929-4936.  [Abstract]

    Western blot analysis of cyclin D1 and MMP 9 in high dose ST2825 treated cells. High dose ST2825 significantly inhibits cyclin D1 expression in osteosarcoma cells, and significantly increases MMP9 protein expression.

    ST 2825 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Oct;16(4):4929-4936.  [Abstract]

    Western blot analysis of p65 and cleaved caspase 3 in high dose ST2825 treated cells. High dose ST2825 significantly inhibits nuclear p65 in osteosarcoma cells, and significantly increases cleaved caspase 3 protein expression.

    ST 2825 purchased from MedChemExpress. Usage Cited in: Exp Neurol. 2017 Sep;295:23-35.  [Abstract]

    Western blotting analysis of the Tyr1472-phosphorylation of the NR2B subunit in the hippocampus of experimental rats under the various treatment conditions. ST2825 (10 μg in 2 μL) is injected. Representative Western blotting bands corresponding to the specific proteins and the various pharmacological treatments.

    ST 2825 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Nov 17;7(1):15797.  [Abstract]

    Representative Western blot to show the level of MyD88 protein. The upper panel shows representative protein levels of MyD88. Tubulin is detected as a loading control. The bottom panel shows quantitative data of MyD88.

    ST 2825 purchased from MedChemExpress. Usage Cited in: Anticancer Res. 2017 Nov;37(11):6203-6209.  [Abstract]

    Effect of ST2825 on the expression of myeloid differentiation primary response gene 88 (MYD88) and nuclear factor kappa B (NF-ĸB) signaling proteins. Cells are cultured with 100 μM ST2825 for 6 h and analysed for protein expression by immunoblotting. DMSO is used as a vehicle control and α-tubulin as a loading control.

    ST 2825 purchased from MedChemExpress. Usage Cited in: Brain Res. 2016 Jul 15;1643:130-9.  [Abstract]

    Effect of ST2825 treatment on the expression of MyD88 at 24h after TBI. Levels of MyD88 are significantly increased at 24 h after TBI. ST2825 (20 μg/μL) treatment reduces the levels of MyD88 at 24 h post TBI. No difference is detected between the TBI group and TBI+vehicle group.

    ST 2825 purchased from MedChemExpress. Usage Cited in: Genet Mol Res. 2016 Mar 4;15(1):15016826.  [Abstract]

    Effect of ST2825 on IκB, cyclin D1, cleaved caspase-3, and bcl-2 expression in HepG-2 cells as determined by western blot analysis (lane 1, blank; lane 2, control; and lane 3, high-dose ST2825). Compared with the control, 24 h of ST2825 treatment significantly inhibits cyclin D1 and bcl-2 expression (P>0.05), but 24-h treatment with ST2825 significantly increases cleaved caspase-3 expression (P<0.05) in the high-dose group.

    ST 2825 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2015 Jul;12(1):895-904.  [Abstract]

    The degradation of IκBα and nuclear translocation of p65 induced by IL-1β are also dramatically blocked by pretreatment of the cells with TLR2Ab, ST2825 and TPCA-1. The cultured leukocytes are obtained from a normal control mouse and stimulated with IL-1β (10 ng/ml) for 1 h with or without pre-treatment of BML-111 (1 mM) for 30 min, BOC1 (100 μM) for 30 min, TLR2Ab (1 μg/mL) for 1 h, goat IgG (1 μg/mL) for 1 h, ST2825 (20 μM) for 1 h or TPCA-1 (10 μM) for 1 h. The western blot is representative

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity[1][2].

    IC50 & Target

    MyD88[1]
    In Vitro

    ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization. ST2825 inhibits this interaction in a concentration-dependent manner with ~40% inhibition of dimerization at 5 μM ST2825 and 80% inhibition at 10 μM ST2825[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    ST 2825 Related Antibodies
    In Vivo

    ST2825 dose-dependently inhibits IL-1β-induced production of IL-6 in treated mice after oral administration. The animals are administered orally with the appropriate vehicles or ST2825 at doses ranging from 50 to 200 mg/kg, 5 min prior to i.p. injection with 20 μg/kg IL-1β. ST2825 exertes a significant inhibition of IL-1β-stimulated production of IL-6 at 100 and 200 mg/kg[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    591.51

    Formula

    C27H28Cl2N4O5S
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(N([C@H]1C(N)=O)[C@@](SCC1)([H])C2)[C@]2(CCC3)N3C(CC4=CC=C(C=C4)NC(COC(C(Cl)=C5)=CC=C5Cl)=O)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (169.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.6906 mL 8.4529 mL 16.9059 mL
    5 mM 0.3381 mL 1.6906 mL 3.3812 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (4.23 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (4.23 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.92%

    SDS (393 KB)

    COA (264 KB) LCMS (94 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [1]

    HeLa cells are seeded at 105 cells/mL in a 96-well tissue-culture plate. After incubating overnight, the medium is discarded, and the cells are added with tissue culture medium, 10% FBS, containing ST2825 at concentrations ranging from 0.1 to 10 μM and DMSO at 0.1% final concentration. The cells are incubated for 6 and 18 h and then added with the yellow XTT (0.3 mg/mL) for further 2 h of incubation. At the end of the incubation periods, reactions are quantified by using a Sirio S Seac microplate reader[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Mice[1]
    Mice (female C57Bl/6) are divided into experimental groups of 15 mice. They are injected i.p. with saline (control animals) or recombinant murine IL-1β (20 μg/kg). A time-course analysis of IL-6 production established that the peak of cytokine is reached 2 h after IL-1β injection. ST2825, administered orally as 0.5% suspension in carboxymethylcellulose (CMC) or CMC alone, is supplied to the experimental mice groups. Two hours after IL-1β injection, the animals are killed, and sera are collected to assay IL-6 levels. Mice, which are treated orally with 100 and 200 mg/kg ST2825, shows lower levels of IL-6 versus CMC-treated mice.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.6906 mL 8.4529 mL 16.9059 mL 42.2647 mL
    5 mM 0.3381 mL 1.6906 mL 3.3812 mL 8.4529 mL
    10 mM 0.1691 mL 0.8453 mL 1.6906 mL 4.2265 mL
    15 mM 0.1127 mL 0.5635 mL 1.1271 mL 2.8176 mL
    20 mM 0.0845 mL 0.4226 mL 0.8453 mL 2.1132 mL
    25 mM 0.0676 mL 0.3381 mL 0.6762 mL 1.6906 mL
    30 mM 0.0564 mL 0.2818 mL 0.5635 mL 1.4088 mL
    40 mM 0.0423 mL 0.2113 mL 0.4226 mL 1.0566 mL
    50 mM 0.0338 mL 0.1691 mL 0.3381 mL 0.8453 mL
    60 mM 0.0282 mL 0.1409 mL 0.2818 mL 0.7044 mL
    80 mM 0.0211 mL 0.1057 mL 0.2113 mL 0.5283 mL
    100 mM 0.0169 mL 0.0845 mL 0.1691 mL 0.4226 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    ST 2825 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    ST 2825894787-30-5ST2825ST-2825MyD88Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    ST 2825
    Cat. No.:
    HY-50937
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.